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Abstract
Background: Atrial fibrillation (AF) is common in older people with frailty and is associated with an increased risk
of stroke and systemic embolism. Whilst oral anticoagulation is associated with a reduction in this risk, there is a
lack of data on the safety and efficacy of direct oral anticoagulants (DOACs) in people with frailty. This study aims
to report clinical outcomes of patients with AF in the Effective Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial by frailty status.
Methods: Post hoc analysis of 20,867 participants in the ENGAGE AF-TIMI 48 trial, representing 98.8% of those
randomised. This double-blinded double-dummy trial compared two once-daily regimens of edoxaban (a DOAC)
with warfarin. Participants were categorised as fit, living with pre-frailty, mild-moderate, or severe frailty according to
a standardised index, based upon the cumulative deficit model. The primary efficacy endpoint was stroke or
systemic embolism and the safety endpoint was major bleeding.
Results: A fifth (19.6%) of the study population had frailty (fit: n = 4459, pre-frailty: n = 12,326, mild-moderate frailty:
n = 3722, severe frailty: n = 360). On average over the follow-up period, the risk of stroke or systemic embolism
increased by 37% (adjusted HR 1.37, 95% CI 1.19–1.58) and major bleeding by 42% (adjusted HR 1.42, 1.27–1.59) for
each 0.1 increase in the frailty index (four additional health deficits). Edoxaban was associated with similar efficacy
to warfarin in every frailty category, and a lower risk of bleeding than warfarin in all but those living with severe
frailty.
Conclusions: Edoxaban was similarly efficacious to warfarin across the frailty spectrum and was associated with
lower rates of bleeding except in those with severe frailty. Overall, with increasing frailty, there was an increase in
stroke and bleeding risk. There is a need for high-quality, frailty-specific population randomised control trials to
guide therapy in this vulnerable population.
Trial registration: ClinicalTrials.gov NCT00781391. First registered on 28 October 2008
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Background
Atrial fibrillation (AF) affects at least 10 million people
in Europe [1]. The incidence and prevalence of AF in-
creases with age [2] and is more common in patients
with frailty [3, 4], a condition characterised by a decline
in a person’s biological reserves and deterioration in
physiological mechanisms that render them vulnerable
to a range of adverse outcomes [5–9]. Frailty provides
an insight into biological age and is more useful than
chronological age in predicting adverse events and guid-
ing clinical care [10–14]. Frailty is commonly identified
using either a frailty index or a frailty phenotype. The
frailty index expresses the proportion of health deficits
that a person has accumulated divided by all deficits
measured, whereas the phenotype defines frailty as poor
performance in three of five criteria (weight loss, exhaus-
tion, weakness, slowness, lack of activity) [7]. There is
overlap between the two approaches [15].
Whilst AF is associated with an increased risk of
stroke and mortality, an appropriate prescription of oral
anticoagulation can reduce the risk of stroke by 64%
[16, 17]. Therefore, anticoagulation is recommended
for men with AF and a CHA2DS2-VASc score of 2 or
greater and in women with a score of 3 or greater
[18, 19]. Large randomised controlled trials have
established the efficacy and safety of direct oral anti-
coagulant medications (DOACs) in comparison to
warfarin for stroke prevention in non-valvular AF
[20–23], including in people aged over 75 years [24],
and they are associated with a per patient cost saving
[25]. However, we lack data on the efficacy and safety
of DOAC in older people with AF who are also frail [3].
Our three objectives for this study were to estimate
the prevalence of frailty in people with AF; describe the
association between AF, frailty, and clinical outcomes;
and compare the efficacy and safety of edoxaban (a
DOAC) to warfarin by frailty category.
Methods
We constructed a frailty index using data from the Ef-
fective Anticoagulation with Factor Xa Next Generation
in Atrial Fibrillation–Thrombolysis in Myocardial Infarc-
tion 48 (ENGAGE AF-TIMI 48) trial [26]. The use of a
frailty index is an established and validated technique for
quantifying frailty using the cumulative deficit model
and results in substantially better prediction of mortality
and other adverse events than age alone [11, 27, 28].
Study cohort
The design and baseline characteristics of the ENGAGE
AF-TIMI 48 study are described elsewhere (NCT00781391)
[21, 26]. In brief, this was a randomised, double-blinded,
double-dummy trial, in which two once-daily regimens of
edoxaban were compared with warfarin in 21,105 patients
with AF and a moderate or high risk of stroke. The trial
was conducted at 1393 centres across 46 countries. Patients
were enrolled from 19 November 2008 to 22 November
2010, and the median follow-up duration was 2.8 years [21].
The protocol and amendments were approved by ethics
committees at each participating centre, and all participants
provided written informed consent. The dataset supporting
the conclusions of this article is available (subject to ap-
proval) via application at https://vivli.org. This post hoc ana-
lysis was approved by an independent review panel. Data
were de-identified at source by the trial team, and patients
that were deemed by the study team to be at high risk of
identification (for example due to a rare medical history)
were excluded from the supplied data set. This left 98.8%
(n = 20,867) of the randomised participants for this analysis
(Fig. 1).
Participants
Patients with AF were eligible for inclusion in the EN-
GAGE AF-TIMI 48 study if they had documented AF of
any duration within the 12 months preceding random-
isation and had a CHADS2 score of 2 or higher. In this
score, 1 point is allocated for each of congestive heart
failure, hypertension, diabetes, and an age of 75 years or
older. A prior stroke or transient ischaemic attack (TIA)
is assigned 2 points. The possible range is 0 to 6, with
higher scores associated with an increased stroke risk.
Exclusion criteria included AF due to a reversible dis-
order, an estimated creatinine clearance of less than 30
ml/min, a high risk of bleeding, use of dual antiplatelet
therapy, moderate-to-severe mitral stenosis, other indi-
cations for anticoagulation therapy; acute coronary syn-
dromes, coronary revascularization, or stroke within 30
days before randomisation; and an inability to adhere to
study procedures [21, 26].
Interventions
The study drugs were warfarin (dose-adjusted to achieve
an international normalised ratio [INR] of 2 to 3), edox-
aban 30 mg daily, or edoxaban 60 mg daily. Patients were
randomised in a 1:1:1 ratio. The allocated dose of edoxa-
ban was halved if the patient had or developed a creatin-
ine clearance of 30–50ml/min, a body weight of 60 kg
or less, or the concomitant use of verapamil or quinidine
(or dronedarone, after a protocol amendment on 22
December 2010). Standard dosing was resumed if there
was no other indication for dose reduction and the
verapamil, quinidine, or dronedarone was stopped.
Outcomes
The primary efficacy endpoint was the time to the first
adjudicated stroke (ischaemic or haemorrhagic) or sys-
temic embolic event. The primary safety endpoint was
adjudicated major bleeding during treatment, as defined
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by the International Society on Thrombosis and Haemo-
stasis [29]. The composite net clinical endpoints were
stroke, systemic embolic event, major bleeding, or death;
disabling stroke, life-threatening bleeding, or death; and
stroke, systemic embolic event, life-threatening bleeding,
or death. Given the established association between
frailty and mortality [5], we report death as a separate
outcome. For composite endpoints involving deaths, in-
dividuals were right censored at death in the analysis.
An independent clinical endpoint committee, who were
blinded to study assignment, adjudicated all deaths and
suspected cerebrovascular events, systemic embolic
events, myocardial infarctions, bleeding events, and
hepatic events [21]. The definitions used by the clinical
endpoint committee are provided in the original study
protocol [26].
Blinding
To maintain blinding, each patient received two sets of
study drugs—with a placebo matching warfarin for
Fig. 1 Consort diagram
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patients in the edoxaban arms or edoxaban for the
patients in the warfarin arms. The INR was measured at
least monthly, with sham results generated in the edoxa-
ban groups.
Frailty
We defined frailty using the cumulative deficit model,
which identifies deficits in health (such as symptoms,
signs, diseases, disabilities, or abnormalities in clinical
investigations) on the basis that the more deficits a per-
son has, the more likely that the person is frail [30]. The
cumulative deficit model enables calculation of a frailty
index as an equally weighted proportion of the number
of deficits present in an individual to the total possible.
For this study, we constructed a frailty index using the
available trial data, calculated at the time of study entry.
In line with the established guidance for constructing a
frailty index, candidate health deficit variables for inclu-
sion were identified on the basis that they were associ-
ated with health status, their prevalence generally
increases with age, they do not reach saturation too early
(over 80% prevalence before the age of 80), and they
cover a range of body systems [31]. Data needed to be
available for at least 70% of items for inclusion [32]. The
40 items included in the construction of the frailty index
are detailed in Additional file 1: Table S1. The presence
or absence of each variable was ascertained from data
collected by the trial investigators as part of their
protocol-specified assessment, which took place within
30 days of study randomisation [33]. Participants were
categorised based upon the frailty index into fit (0 to <
0.12), living with pre-frailty (≥ 0.12 to < 0.24), mild-
moderate (≥ 0.24 to < 0.36), and severe frailty (≥ 0.36 to
1.0), based upon thresholds that are commonly used in
the literature [11, 34].
Statistical methods
Baseline characteristics are reported for the frailty
groups and by treatment allocation. Continuous vari-
ables are presented as medians with interquartile range,
and categorical variables as counts and proportions.
Event rates for each of the primary and secondary (com-
posite) outcomes were calculated as the number of events
per 100 person-years and reported by frailty category and
treatment arm.
Cox proportional hazard models were used to (1) test
whether each regimen of edoxaban was non-inferior to
warfarin for each primary and secondary (composite)
outcomes, stratified by frailty category, and (2) quantify
the association between frailty category and the primary
and secondary (composite) outcomes, with the treatment
arm included as an interaction term. The proportional
hazards assumption was assessed using Schoenfeld resid-
uals tests. Hazard ratios with 95% confidence intervals
(CIs) were reported for each. As the trial participants
were randomised by treatment allocation, but not frailty,
comparisons by frailty were adjusted for age, sex, race,
and region. These limited adjustments were made to
preserve the association between frailty and outcomes.
Finally, the impact of an increase of 0.1 in frailty index
on each clinical outcome for the complete analytical co-
hort was calculated. Hazard ratios were adjusted for the
treatment group and reported alongside estimates fur-
ther adjusted for age, sex, race, and region, in the whole
cohort. A sensitivity analysis was completed for the asso-
ciation between frailty and the clinical outcomes, where
frailty index items were removed if they were related to
bleeding (history of non-intracranial bleeding and peptic




We include 20,867 participants in the analysis (38.1%
women [n = 7940]; 86.8% 60 years or older [n = 18,119];
25.5% with paroxysmal AF [n = 5311]; Fig. 1, Table 1).
Overall, 21.4% (n = 4459) of participants were cate-
gorised as fit; 59.1% (n = 12,326) were pre-frail; 17.8%
(n = 3722) had mild-moderate frailty; and 1.7% (n = 360)
had severe frailty (Additional file 1: Fig. S1). The pre-
dicted stroke risk was higher with increased frailty
(mean CHADS2 score: fit 2.39, pre-frail 2.80, mild-
moderate frailty 3.37, severe 4.03).
There was a similar number of participants in each
treatment arm (warfarin 33.3% [n = 6957]; edoxaban 30
mg 33.3% [n = 6956]; edoxaban 60 mg 33.3% [n = 6954]),
and the distribution of frailty category was comparable
between treatment arms (Fig. 1). The characteristics of
patients in each treatment group, stratified by frailty, are
reported in Additional file 1: Table S2.
Primary outcomes
Across the three treatment arms, 997 patients experi-
enced stroke or systemic embolism (rate per 100 person-
years: warfarin 1.73 [95% CI 1.54–1.92]; edoxaban 30mg
1.95 [1.76–2.15]; edoxaban 60mg 1.47 [1.30–1.64];
Table 2). There was no difference in stroke or systemic
embolism between the treatment arms (Additional file 1:
Table S3), including when stratified by frailty category
(Table 3). Across the treatment arms, in comparison to
the fit group, the average adjusted risk of stroke or sys-
temic embolism over the follow-up period was 84%
higher in the group living with mild-moderate frailty
and more than double in those living with severe frailty
(Table 4). On average over the follow-up period, for each
increase of 0.1 in the frailty index (four additional health
deficits), the risk of stroke or systemic embolism in-
creased by 37% (adjusted HR 1.37, 1.19–1.58).
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Table 1 Baseline characteristics of participants by frailty category
Frailty category
All Fit Pre-fail Mild-moderate Severe
n (%) 20,867 4459 (21.4) 12,326 (59.1) 3722 (17.8) 360 (1.7)
Mean frailty index (SD) 0.18 (0.07) 0.09 (0.02) 0.18 (0.03) 0.28 (0.03) 0.40 (0.03)
Demographics
Age, n (%)
< 60 years 2748 (13.2) 739 (16.6) 1671 (13.6) 319 (8.6) 19 (5.3)
60–69 years 5875 (28.2) 1245 (27.9) 3583 (29.1) 979 (26.3) 68 (18.9)
70–79 8716 (41.8) 1795 (40.3) 5111 (41.5) 1641 (44.1) 169 (46.9)
80+ years 3528 (16.9) 680 (15.3) 1961 (15.9) 783 (21.0) 104 (28.9)
Female sex, n (%) 7940 (38.1) 1470 (33.0) 4685 (38.0) 1619 (43.5) 166 (46.1)
Region, n (%)
North America 4654 (22.3) 721 (16.2) 2639 (21.4) 1153 (31.0) 141 (39.2)
Latin America 2647 (12.7) 898 (20.1) 1484 (12.0) 252 (6.8) 13 (3.6)
Western Europe 3091 (14.8) 743 (16.7) 1804 (14.6) 492 (13.2) 52 (14.4)
Eastern Europe 7105 (34.0) 1143 (25.6) 4392 (35.6) 1442 (38.7) 128 (35.6)
Asia-Pacific and South Africa 3370 (16.1) 954 (21.4) 2007 (16.3) 383 (10.3) 26 (7.2)
Clinical
Paroxysmal AF, n (%) 5311 (25.5) 1073 (24.1) 3195 (25.9) 958 (25.8) 85 (23.6)
Qualifying risk factor, n (%)
Age ≥ 75 8356 (40.0) 1799 (40.3) 4693 (38.1) 1669 (44.8) 195 (54.2)
Prior stroke or TIA 5909 (28.3) 988 (22.2) 3345 (27.1) 1398 (37.6) 178 (49.4)
Congestive heart failure 11,967 (57.3) 1993 (44.7) 7075 (57.4) 2601 (69.9) 298 (82.8)
Diabetes mellitus 7546 (36.2) 825 (18.5) 4478 (36.3) 1989 (53.4) 254 (70.6)
Hypertension 19,454 (93.2) 4083 (91.6) 11,518 (93.4) 3506 (94.2) 347 (96.4)
CHADS2 score
Mean score (SD) 2.83 (0.98) 2.39 (0.67) 2.80 (0.91) 3.37 (1.11) 4.03 (1.19)
≤ 3, n (%) 16,167 (77.5) 4099 (91.9) 9739 (79.0) 2193 (58.9) 136 (37.8)
4–6, n (%) 4699 (22.5) 360 (8.1) 2587 (21.0) 1528 (41.1) 224 (62.2)
Dose reduction*, n (%) 5302 (25.4) 1020 (22.9) 2885 (23.4) 1237 (33.2) 160 (44.4)
Cr clearance ≤ 50 ml/min 3975 (19.2) 613 (13.9) 2119 (17.3) 1083 (29.5) 160 (45.5)
Weight≤ 60 kg 2063 (9.9) 524 (11.8) 1182 (9.6) 341 (9.2) 16 (4.4)
Use of verapamil or qunidine 701 (3.4) 183 (4.1) 394 (3.2) 116 (3.1) 8 (2.2)
Previous VKA for ≥ 60 days, n (%) 12,305 (59.0) 2509 (56.3) 7241 (58.7) 2303 (61.9) 252 (70.0)
Medication at time of randomisation, n (%)
Aspirin 6121 (29.3) 1107 (24.8) 3650 (29.6) 1234 (33.2) 130 (36.1)
Thienopyridine 480 (2.3) 62 (1.4) 264 (2.1) 140 (3.8) 14 (3.9)
Amiodarone 2441 (11.7) 501 (11.2) 1397 (11.3) 489 (13.1) 54 (15.0)
Digoxin or digitalis preparation 6271 (30.1) 1269 (28.5) 3713 (30.1) 1172 (31.5) 117 (32.5)
Treatment allocation, n (%)
Warfarin 6957 (33.3) 1479 (33.2) 4130 (33.5) 1230 (33.0) 118 (32.8)
Edoxaban 30 mg 6956 (33.3) 1473 (33.0) 4122 (33.4) 1247 (33.5) 114 (31.7)
Edoxaban 60 mg 6954 (33.3) 1507 (33.8) 4074 (33.1) 1245 (33.4) 128 (35.6)
Abbreviations: AF atrial fibrillation, Cr creatinine, SD standard deviation, TIA transient ischaemic attack, VKA vitamin K antagonist
*At randomisation
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Overall, 1185 participants experienced major bleeding
during treatment (rate per 100 person-years: warfarin
2.76, 95% CI 2.52–3.00; edoxaban 30mg 1.28, 1.12–1.44;
edoxaban 60mg 2.17, 1.96–2.38; Table 2). On average
over the follow-up period, bleeding events were 53%
lower in patients taking edoxaban 30 mg compared to
warfarin (HR 0.47, 95% CI 0.40–0.54) and 21% lower in
those taking edoxaban 60 mg (HR 0.79, 0.69–0.89,
Table 2 Numbers and rates of outcome events
Frailty category
All Fit Pre-frail Mild-moderate Severe
Primary end points
Time to the first adjudicated
stroke or systemic embolism
Warfarin 333 55 185 83 10
1.73 (1.54 - 1.92) 1.29 (0.95 - 1.63) 1.61 (1.38 - 1.84) 2.58 (2.03 - 3.14) 3.40 (1.29 - 5.51)
Edoxaban 30mg 378 56 219 100 3
1.95 (1.76 - 2.15) 1.34 (0.99 - 1.69) 1.90 (1.64 - 2.15) 3.00 (2.41 - 3.59) 1.04 (0.00 - 2.21)
Edoxaban 60mg 286 58 151 71 6
1.47 (1.30 - 1.64) 1.35 (1.00 - 1.70) 1.31 (1.11 - 1.52) 2.13 (1.64 - 2.63) 1.85 (0.37 - 3.34)
Time to the first adjudicated
major bleeding during
treatment
Warfarin 522 84 298 122 18
2.76 (2.52 - 3.00) 2.01 (1.58 - 2.44) 2.64 (2.34 - 2.95) 3.85 (3.17 - 4.53) 6.39 (3.44 - 9.35)
Edoxaban 30mg 249 35 141 60 13
1.28 (1.12 - 1.44) 0.83 (0.56 - 1.11) 1.22 (1.02 - 1.42) 1.80 (1.34 - 2.25) 4.74 (2.16 - 7.31)
Edoxaban 60mg 414 82 227 93 12
2.17 (1.96 - 2.38) 1.94 (1.52 - 2.36) 2.01 (1.75 - 2.27) 2.86 (2.28 - 3.44) 3.80 (1.65 - 5.95)
Composite net clinical endpoints
Stroke, systemic embolic
event, major bleeding or
death
Warfarin 1462 205 811 393 53
7.90 (7.50 - 8.31) 4.97 (4.29 - 5.65) 7.34 (6.84 - 7.85) 12.86 (11.59 - 14.14) 19.41 (14.19 - 24.64)
Edoxaban 30mg 1247 185 686 335 41
6.58 (6.22 - 6.95) 4.48 (3.83 - 5.13) 6.06 (5.61 - 6.52) 10.35 ( 9.24 - 11.46) 15.71 (10.90 - 20.52)
Edoxaban 60mg 1321 231 685 361 44




Warfarin 981 124 529 285 43
5.07 (4.75 - 5.39) 2.91 (2.39 - 3.42) 4.58 (4.19 - 4.98) 8.79 (7.77 - 9.82) 14.58 (10.22 - 18.93)
Edoxaban 30mg 836 124 448 236 28
4.26 (3.97 - 4.55) 2.93 (2.42 - 3.45) 3.83 (3.47 - 4.18) 6.95 (6.06 - 7.83) 9.69 ( 6.10 - 13.28)
Edoxaban 60mg 882 139 454 259 30




Warfarin 1109 145 603 315 46
5.80 (5.45 - 6.14) 3.43 (2.87 - 3.98) 5.28 (4.86 - 5.70) 9.88 ( 8.79 - 10.98) 15.91 (11.31 - 20.51)
Edoxaban 30mg 999 148 542 280 29
5.16 (4.84 - 5.48) 3.53 (2.96 - 4.10) 4.69 (4.30 - 5.09) 8.42 (7.43 - 9.40) 10.09 ( 6.42 - 13.77)
Edoxaban 60mg 990 168 501 287 34
5.12 (4.80 - 5.43) 3.92 (3.33 - 4.52) 4.38 (3.99 - 4.76) 8.70 (7.70 - 9.71) 10.51 ( 6.98 - 14.04)
Death Warfarin 837 100 447 252 38
4.27 (3.98 – 4.56) 2.32 (1.86 – 2.77) 3.82 (3.47 – 4.18) 7.62 (6.68 – 8.56) 12.54 (8.56 – 16.53)
Edoxaban 30mg 736 107 387 217 25
3.79 (3.52 – 4.06) 2.51 (2.03 – 2.99) 3.37 (3.04 – 3.71) 6.34 (5.50 – 7.18) 8.46 (5.14 – 11.77)
Edoxaban 60mg 772 121 391 231 29
3.92 (3.64 – 4.19) 2.77 (2.28 – 3.27) 3.38 (3.05 – 3.72) 6.81 (5.93 – 7.68) 8.71 (5.54 – 11.89)
Each cell shows number, and incidence rates per 100 person years (95% confidence interval)
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Additional file 1: Table S3). When stratified by frailty
category, edoxaban 30mg was associated with a reduc-
tion in major bleeding compared with warfarin in all but
those with severe frailty, and edoxaban 60mg with a
reduction in major bleeding in the pre-frail and mild-
moderate frailty groups only (Table 3). Across the treat-
ment arms, the adjusted risk of major bleeding increased
with the frailty category, such that for each increase of
0.1 in the frailty index (four additional health deficits),
the risk of major bleeding increased by 42% on average
over the follow-up period (adjusted HR 1.42, 1.27–1.59).
Composite net clinical endpoints
Overall, 4030 participants experienced stroke, systemic
embolic event, major bleeding, or death (rate per 100
person-years: warfarin 7.90, 95% CI 7.50–8.31; edoxaban
30mg 6.58, 6.22–6.95; edoxaban 60mg 7.06, 6.68–7.44;
Table 2). Disabling stroke, life-threatening bleeding, or
death affected 2699 participants (rates: warfarin 5.07,
4.75–5.39; edoxaban 30mg 4.26, 3.97–4.55; edoxaban
60mg 4.52, 4.22–4.81; Table 2). Stroke, systemic em-
bolic event, life-threatening bleeding, or death affected
3098 participants (rates: warfarin 5.80, 5.45–6.14; edoxa-
ban 30 mg 5.16, 4.84–5.48; edoxaban 60mg 5.12, 4.80–
5.43; Table 2).
Compared with warfarin, there was a significant reduc-
tion for each of the three composite outcomes associated
with the use of edoxaban at both 30-mg and 60-mg dos-
ages (Additional file 1: Table S3). When stratified by
frailty category, there was no difference in each of the
three composite outcomes according to the treatment
arm for those in the fit category (Table 3). In those living
with pre-frailty, a reduction in all three composite out-
comes was associated with edoxaban 60mg compared
with warfarin. For edoxaban 30 mg, the risk was reduced
in composite outcome (1) stroke, systemic embolic
event, major bleeding, or death and (2) disabling stroke,
life-threatening bleeding, or death—but not for the com-
posite outcome (3) stroke, systemic embolic event, life-
threatening bleeding, or death. For those living with
mild-moderate frailty, there was a reduction in (1) and
(2) with the 30-mg dose, and no difference in the com-
posite outcomes between the use of edoxaban 60 mg
and warfarin. Finally, in those with severe frailty, there
Table 4 The association between frailty category and clinical outcomes
Hazard ratio (95% CI)
Fit Pre-frail Mild-moderate frailty Severe frailty
Primary endpoints
Time to first adjudicated stroke
or systemic embolism
Unadjusted 1 1.22 (1.03–1.45) 1.93 (1.59–2.35) 1.58 (0.99–2.55)
Adjusted 1 1.22 (0.90–1.65) 1.84 (1.31–2.59) 2.30 (1.17–4.52)
Time to adjudicated major
bleeding during treatment
Unadjusted 1 1.22 (1.04–1.43) 1.75 (1.46–2.09) 3.02 (2.17–4.20)
Adjusted 1 1.32 (1.04–1.68) 1.79 (1.36–2.37) 2.86 (1.72–4.76)
Composite net clinical endpoints
Stroke, systemic embolic event,
major bleeding, or death
Unadjusted 1 1.30 (1.19–1.43) 2.31 (2.09–2.55) 3.29 (2.74–3.96)
Adjusted 1 1.49 (1.28–1.74) 2.45 (2.07–2.90) 3.56 (2.63–4.81)
Disabling stroke, life-threatening
bleeding, or death
Unadjusted 1 1.37 (1.22–1.53) 2.60 (2.30–2.94) 3.69 (2.96–4.59)
Adjusted 1 1.60 (1.32–1.95) 2.88 (2.33–3.55) 4.59 (3.24–6.50)
Stroke, systemic embolic event,
life-threatening bleeding, or death
Unadjusted 1 1.32 (1.19–1.47) 2.49 (2.22–2.78) 3.36 (2.73–4.14)
Adjusted 1 1.56 (1.30–1.87) 2.73 (2.24–3.33) 4.24 (3.04–5.91)
Death
Unadjusted 1 1.40 (1.24–1.58) 2.75 (2.41–3.13) 3.94 (3.13–4.97)
Adjusted 1 1.68 (1.36–2.09) 3.13 (2.48–3.95) 4.97 (3.42–7.23)
Adjustments made for sex, age, race, and region. Interaction by treatment group: not significant
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was a reduction in (2) with edoxaban 60 mg compared
to warfarin, and no difference in the composite out-
comes between edoxaban 30mg and warfarin, and for
the other composite outcomes for the 60-mg dosage
(Table 2).
When modelling frailty index on a continuous scale,
there was a significantly increased risk of all three com-
posite outcomes with increasing frailty across all three
treatment arms. For each increase of 0.1 in the frailty
index (four additional health deficits), the adjusted risks
on average over the follow-up period of (1) stroke, sys-
temic embolic event, major bleeding, or death increased
by 59% (HR 1.59, 1.48–1.69); (2) disabling stroke, life-
threatening bleeding, or death by 72% (1.72, 1.59–1.87);
and (3) stroke, systemic embolic event, life-threatening
bleeding, or death by 67% (1.67, 1.55–1.80). The overall
findings were robust to a sensitivity analysis in which the
frailty index was modified to remove factors specifically
associated with bleeding risk (Additional file 1: Table S4).
Mortality
There was a stepwise association between frailty cat-
egory and mortality, whereby patients with severe frailty
had a hazard ratio for mortality of 4.97 (3.42–7.23) com-
pared to the fit group (Table 4). Mortality accounted for
a greater proportion of the composite endpoints with in-
creasing frailty category (Table 2).
Discussion
In this analysis of a large international clinical trial, we have
shown that edoxaban is non-inferior to warfarin across the
frailty spectrum in stroke prevention. Bleeding events were
reduced in patients who received edoxaban except in those
living with severe frailty—where standardised bleeding
event rates were not statistically significantly different from
warfarin. We found that just one in five trial participants
had frailty and that frailty was associated with worse clinical
outcomes, regardless of treatment arm allocation.
The key finding of the ENGAGE AF-TIMI 48 trial was
that edoxaban was associated with lower rates of bleed-
ing and death from cardiovascular causes compared with
warfarin, with similar efficacy in stroke and systemic em-
bolism prophylaxis. In our stratified analyses, however,
these findings were not upheld for every frailty category.
Instead, it appeared that the effect was driven by the
pre-frail group, which was the most prevalent frailty cat-
egory in the trial population. This may relate to a lack of
statistical power, particularly as the trend in every sub-
group is consistent with the overall trial finding. Even
so, we cannot conclude with certainty from this analysis
that the overall trial findings are applicable to patients
living with severe frailty. Here, those patients were
under-represented, even though they are a group at high
risk of stroke, and in whom AF is common [3, 4].
The distribution of the frailty scores in this trial is strik-
ing. One in five participants was frail, and just one in 50
had severe frailty. This is in contrast with the primary care
population of older people with AF, in which over half live
with moderate or severe frailty [4]. It is known that health
problems tend to accumulate with age and therefore
frailty is generally progressive [35], with an average rate of
deficit accumulation in community-dwelling older people
of 3% per year [36]. With population ageing, the burden of
frailty is likely to grow substantially [37], amplifying the
need for robust trial data that is specific to people with
frailty who are at particular risk of treatment-related
harm. The perception of a gap between the representation
of people with frailty in trials and the clinical population
may explain, at least in part, the relatively low ‘real-world’
prescription rates of oral anticoagulation for eligible pa-
tients [38–40] and may reflect clinicians’ fear of causing
iatrogenic harm, particularly in people with frailty [3].
This must be considered alongside our finding that death
is more common in patients with AF and also frailty—
which is well known in a general population [10–14].
We have demonstrated that frailty is associated with
worse clinical outcomes regardless of treatment arm al-
location. The risk of every trial endpoint was at least
doubled for patients with severe frailty compared to the
fit group, with the appearance of a ‘dose-response rela-
tionship’ despite therapy. This is a population with a
high baseline risk of cardiovascular events and death,
and a high residual risk remains, despite therapy. This
risk is likely to be multifactorial, including non-embolic
stroke and death from non-cardiovascular causes that
may not be modifiable in the context of advancing
multi-organ disease. That the risk of major bleeding on
treatment was substantially higher with increasing frailty
category may represent a target for improvement. Modifi-
able bleeding risk factors should be optimised—including
a review of concomitant antiplatelet and non-steroidal
anti-inflammatory medications [19], as well as a renewed
focus on DOAC dosing, which may be complex and is
commonly incorrect [41].
A recent randomised controlled trial found that in older
Japanese patients, a daily 15-mg dose of edoxaban was su-
perior to placebo in preventing stroke or systemic embol-
ism, without a significantly higher incidence of major
bleeding than placebo [42]. These findings are important,
but we know that there is a graded degree of risk amongst
older people of the same age [4, 7, 10, 30], and there re-
mains a notable lack of generalisable data concerning the
outcomes associated with anticoagulation for patients with
more advanced frailty [3]. There are many reasons why
older people are historically under-represented in clinical
trials, including the presence of co-morbidities, communi-
cation issues, and physical immobility that limit opportun-
ities for participation [43]. Yet, in view of a high baseline
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risk of both stroke and iatrogenic harm, there is a strong
argument for frailty-specific population randomised trials
in this area. In lieu of specific randomised evidence to
quantify efficacy and safety in older people with severe
frailty, future work modelling outcomes using a combin-
ation of epidemiological and trial data may yield interest-
ing insights [44, 45].
This study has strengths, which include the ENGAGE
AF-TIMI 48 dataset, in which there were few missing
data, a large sample size, and a long follow-up duration
[21, 26]. To our knowledge, this study is the first to
report the outcomes of such a trial by frailty [3]. As the
recruitment of patients with frailty into clinical trials is
challenging, these analyses are necessary and important
in order to guide clinicians and individualise therapy
[46]. Frailty was identified using a conceptually robust
and reproducible measure [31], that is increasingly used
in understanding the relationship between age and
outcomes in clinical trials [10], and allows the risk of
adverse outcomes to be defined more precisely than a
phenotypic approach [15]. We adjusted the associations
between frailty and outcomes for potential confounders.
However, we recognise the limitations of our work. In
particular, the trial exclusion criteria mean that patients
with more severe frailty were excluded, for example
patients with a life expectancy of less than 12months or
who were unable to attend for trial visits [26]. This
means that the results are not generalisable to the whole
population of older people with frailty. Secondly, whilst
we did not have access to the complete dataset, the rates
of the outcomes were similar to those in the original
trial [26]. Thirdly, as the trial was not designed for the
analyses that we have undertaken, the analyses stratified
by frailty category are likely to be underpowered.
Fourthly, data were not available to evaluate phenotypic-
ally defined frailty in this dataset. Finally, the study was
conducted in the era before specific reversal agents,
which may impact upon bleeding severity and associated
mortality in future clinical practice.
Conclusion
Patients with AF taking anticoagulation with warfarin or
edoxaban are at substantially higher risk of stroke or sys-
temic embolism, major bleeding during treatment, and
death if they also have frailty. We showed important dif-
ferences in the overall risk of adverse outcomes increasing
with frailty, and efficacy was similar between warfarin and
edoxaban. Whilst a reduction in bleeding was associated
with edoxaban overall, this was not substantiated across
all frailty categories, and people with more advanced
frailty made up a small proportion of the overall trial
population. This highlights the need for high-quality,
frailty-specific population randomised controlled trials to
guide therapy in this vulnerable population.
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